Point72 DIFC Ltd Takes $660,000 Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Point72 DIFC Ltd bought a new position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 16,779 shares of the company's stock, valued at approximately $660,000.

A number of other large investors have also recently made changes to their positions in APGE. Vanguard Group Inc. grew its holdings in Apogee Therapeutics by 60.7% during the 1st quarter. Vanguard Group Inc. now owns 1,868,666 shares of the company's stock worth $124,173,000 after acquiring an additional 705,795 shares in the last quarter. Wellington Management Group LLP grew its stake in shares of Apogee Therapeutics by 0.3% during the fourth quarter. Wellington Management Group LLP now owns 1,591,478 shares of the company's stock worth $44,358,000 after purchasing an additional 4,749 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Apogee Therapeutics by 51.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,170,327 shares of the company's stock valued at $77,770,000 after buying an additional 399,646 shares during the last quarter. Darwin Global Management Ltd. acquired a new stake in Apogee Therapeutics in the first quarter valued at $55,300,000. Finally, Braidwell LP lifted its holdings in Apogee Therapeutics by 38.7% during the 4th quarter. Braidwell LP now owns 681,101 shares of the company's stock worth $19,030,000 after buying an additional 189,988 shares during the last quarter. 79.04% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Apogee Therapeutics

In related news, CFO Jane Henderson sold 6,000 shares of the business's stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $48.26, for a total value of $289,560.00. Following the completion of the sale, the chief financial officer now directly owns 200,871 shares of the company's stock, valued at $9,694,034.46. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other Apogee Therapeutics news, CFO Jane Henderson sold 6,000 shares of Apogee Therapeutics stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $48.26, for a total transaction of $289,560.00. Following the transaction, the chief financial officer now owns 200,871 shares of the company's stock, valued at $9,694,034.46. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Michael Thomas Henderson sold 40,000 shares of the business's stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $47.62, for a total value of $1,904,800.00. Following the completion of the sale, the chief executive officer now owns 1,394,487 shares of the company's stock, valued at approximately $66,405,470.94. The disclosure for this sale can be found here. Insiders have sold 120,995 shares of company stock valued at $5,218,774 in the last ninety days. Insiders own 36.10% of the company's stock.

Apogee Therapeutics Stock Performance

Shares of NASDAQ:APGE traded down $0.33 on Thursday, hitting $57.38. 129,215 shares of the company's stock were exchanged, compared to its average volume of 517,275. Apogee Therapeutics, Inc. has a 1-year low of $14.19 and a 1-year high of $72.29. The company has a market capitalization of $2.58 billion, a PE ratio of -10.99 and a beta of 2.74. The firm's 50-day moving average is $48.52 and its 200 day moving average is $49.84.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.60) EPS for the quarter, meeting the consensus estimate of ($0.60). On average, analysts anticipate that Apogee Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.